Department of Pharmacy, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, NC, USA.
Department of Clinical Pharmacy and Translational Science, University of Tennessee Health Science Center College of Pharmacy, Memphis, TN, USA.
Ann Pharmacother. 2024 Mar;58(3):322-332. doi: 10.1177/10600280231179999. Epub 2023 Jun 21.
Evaluate available evidence of physical and/or chemical compatibility of commonly used medications in critically ill patients with balanced crystalloids.
Ovid MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews were queried from inception to September 2022.
This review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. English-language studies reporting physical and/or chemical compatibility data between 50 selected medications and balanced crystalloids were included. A previously designed tool to assess risk of bias was adapted for use.
Twenty-nine studies encompassing 39 (78%) medications and 188 unique combinations with balanced crystalloids were included. Combinations included 35 (70%) medications with lactated Ringer's, 26 (52%) medications with Plasma-Lyte, 10 (20%) medications with Normosol, and one (2%) medication with Isolyte. Studies commonly evaluated physical and chemical compatibility (55.2%). More medications were evaluated via Y-site than admixture. Incompatibilities were identified in 18% of combinations comprising 13 individual drugs.
This systematic review evaluates the compatibility of select critical care medications with balanced crystalloid solutions. Results may be used as a tool to guide clinicians on balanced crystalloid compatibility, potentially increasing ubiquitous use and reducing patient exposure to normal saline.
Data are limited regarding chemical/physical compatibility of commonly used medications in critically ill patients with balanced crystalloids. Additional compatibility studies are warranted, particularly methodologically rigorous studies assessing Plasma-Lyte, Normosol, and Isolyte. Of the evaluated medications, there was a low frequency of incompatibilities with balanced crystalloids.
评估在重症患者中使用平衡晶体液时,常用药物的物理和/或化学相容性的现有证据。
从建库至 2022 年 9 月,检索 Ovid MEDLINE、Embase、Cochrane 对照试验中心注册库和 Cochrane 系统评价数据库。
本综述的开展符合系统评价和荟萃分析的首选报告项目的要求。纳入报告了 50 种选定药物与平衡晶体液之间的物理和/或化学相容性数据的英文研究。使用先前设计的工具来评估偏倚风险。
纳入了 29 项研究,共涉及 39(78%)种药物和 188 种与平衡晶体液的独特组合。组合包括 35(70%)种药物与乳酸林格氏液、26(52%)种药物与 Plasma-Lyte、10(20%)种药物与 Normosol 和 1 种(2%)药物与 Isolyte。研究通常评估物理和化学相容性(55.2%)。通过 Y 型部位评估的药物比混合药物更多。在包含 13 种个别药物的 18%的组合中发现了不相容性。
本系统评价评估了选定的重症监护药物与平衡晶体溶液的相容性。结果可作为指导临床医生进行平衡晶体相容性的工具,可能会增加广泛应用,并减少患者暴露于生理盐水的风险。
关于在重症患者中使用平衡晶体液时,常用药物的化学/物理相容性的数据有限。需要进行更多的相容性研究,特别是对 Plasma-Lyte、Normosol 和 Isolyte 进行方法学严谨的研究。在所评估的药物中,与平衡晶体液的不相容性频率较低。